PDF(Pubmed)
Abstract：
UNASSIGNED: Dexmedetomidine (DEX) administration decreases post-operative nausea and vomiting (PONV), but it is a lack of large-scale retrospective cohort study and is unclear whether there is a dose-relationship and optimal dose for antiemetic effects between DEX and PONV. We performed a large-scale retrospective cohort study to explore the optimal dose of intraoperative DEX for antiemetic effects of PONV.
UNASSIGNED: A total of 5,310 patients aged ≥18 who underwent elective thoracic surgery from January 2016 to March 2020 under total intravenous anesthesia (TIVA) or combined intravenous and inhalation anesthesia in Henan Provincial People\'s Hospital. Patients were divided into two groups, those who received DEX intraoperatively and those who did not receive DEX. Patients who received DEX after surgery were excluded. Our primary outcomes were the association, the dose-response relationship, and the optimal dose for antiemetic effects between intraoperative DEX and PONV.
UNASSIGNED: Among the 3,878 patients enrolled, 2,553 patients received DEX and 1,325 patients did not receive DEX. The incidence of PONV in patients who received DEX was 21.3%, and the incidence of PONV in patients who did not receive DEX was 46.5% (P = 0.001). After the matched-pairs cohort consisted of 1,325 patients, the incidence of PONV in patients who received DEX was 23.6%, and the incidence of PONV in patients who did not receive DEX was 46.5% (P = 0.001). We analyzed three different models after propensity matching to validate the stability of the prediction model between intraoperative DEX and PONV. A dose-response relationship between intraoperative DEX and PONV was observed. The optimal dose range of intraoperative DEX for antiemetic effects of PONV is 50-100 μg in elective thoracic surgery.
UNASSIGNED: Intraoperative DEX was associated with a decreased incidence of PONV in the large-scale retrospective cohort study. A dose-response relationship between intraoperative DEX and PONV was observed. The optimal dose range of intraoperative DEX for antiemetic effects of PONV is 50-100 μg in elective thoracic surgery.
UNASSIGNED: A total of 5,310 patients aged ≥18 who underwent elective thoracic surgery from January 2016 to March 2020 under total intravenous anesthesia (TIVA) or combined intravenous and inhalation anesthesia in Henan Provincial People\'s Hospital. Patients were divided into two groups, those who received DEX intraoperatively and those who did not receive DEX. Patients who received DEX after surgery were excluded. Our primary outcomes were the association, the dose-response relationship, and the optimal dose for antiemetic effects between intraoperative DEX and PONV.
UNASSIGNED: Among the 3,878 patients enrolled, 2,553 patients received DEX and 1,325 patients did not receive DEX. The incidence of PONV in patients who received DEX was 21.3%, and the incidence of PONV in patients who did not receive DEX was 46.5% (P = 0.001). After the matched-pairs cohort consisted of 1,325 patients, the incidence of PONV in patients who received DEX was 23.6%, and the incidence of PONV in patients who did not receive DEX was 46.5% (P = 0.001). We analyzed three different models after propensity matching to validate the stability of the prediction model between intraoperative DEX and PONV. A dose-response relationship between intraoperative DEX and PONV was observed. The optimal dose range of intraoperative DEX for antiemetic effects of PONV is 50-100 μg in elective thoracic surgery.
UNASSIGNED: Intraoperative DEX was associated with a decreased incidence of PONV in the large-scale retrospective cohort study. A dose-response relationship between intraoperative DEX and PONV was observed. The optimal dose range of intraoperative DEX for antiemetic effects of PONV is 50-100 μg in elective thoracic surgery.
摘要：
未经批准：右美托咪定（DEX）可减少术后恶心和呕吐（PONV），但缺乏大规模的回顾性队列研究,尚不清楚DEX和PONV之间的止吐作用是否存在剂量关系和最佳剂量.我们进行了一项大规模的回顾性队列研究，以探索术中DEX对PONV止吐作用的最佳剂量。
UNASSIGNED：河南省人民医院2016年1月至2020年3月在全静脉麻醉（TIVA）或静脉吸入复合麻醉下择期开胸手术的年龄≥18岁患者共5310例。患者分为两组，术中接受DEX的人和未接受DEX的人。手术后接受DEX的患者被排除在外。我们的主要结果是关联，剂量-反应关系，术中DEX和PONV之间止吐作用的最佳剂量。
未经证实：在3,878名患者中，2,553名患者接受DEX，1,325名患者未接受DEX。接受DEX的患者PONV的发生率为21.3%,未接受DEX的患者的PONV发生率为46.5%(P=0.001).配对队列由1,325名患者组成，接受DEX的患者PONV的发生率为23.6％，未接受DEX的患者的PONV发生率为46.5%(P=0.001).我们在倾向匹配后分析了三种不同的模型，以验证术中DEX和PONV之间预测模型的稳定性。观察术中DEX与PONV之间的剂量-反应关系。在择期胸外科手术中，术中DEX对PONV止吐作用的最佳剂量范围为50-100μg。
UNASSIGNED：在大规模回顾性队列研究中，术中DEX与PONV发生率降低相关。观察术中DEX与PONV之间的剂量-反应关系。在择期胸外科手术中，术中DEX对PONV止吐作用的最佳剂量范围为50-100μg。
UNASSIGNED：河南省人民医院2016年1月至2020年3月在全静脉麻醉（TIVA）或静脉吸入复合麻醉下择期开胸手术的年龄≥18岁患者共5310例。患者分为两组，术中接受DEX的人和未接受DEX的人。手术后接受DEX的患者被排除在外。我们的主要结果是关联，剂量-反应关系，术中DEX和PONV之间止吐作用的最佳剂量。
未经证实：在3,878名患者中，2,553名患者接受DEX，1,325名患者未接受DEX。接受DEX的患者PONV的发生率为21.3%,未接受DEX的患者的PONV发生率为46.5%(P=0.001).配对队列由1,325名患者组成，接受DEX的患者PONV的发生率为23.6％，未接受DEX的患者的PONV发生率为46.5%(P=0.001).我们在倾向匹配后分析了三种不同的模型，以验证术中DEX和PONV之间预测模型的稳定性。观察术中DEX与PONV之间的剂量-反应关系。在择期胸外科手术中，术中DEX对PONV止吐作用的最佳剂量范围为50-100μg。
UNASSIGNED：在大规模回顾性队列研究中，术中DEX与PONV发生率降低相关。观察术中DEX与PONV之间的剂量-反应关系。在择期胸外科手术中，术中DEX对PONV止吐作用的最佳剂量范围为50-100μg。
